Trius Therapeutics (TSRX)
I bought $TSRX trade call target = $6 +
Trius is expecting top-line data from its 2nd Phase III trial of Tedizolid (TR-701) vs. Linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI) by the end of the current quarter.
Tedizolid is an antibiotic designed to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
MRSA issues have been news headlines lately, just google about MSRA infections on the serious rise, and tweet @iggyigette who is a Doctor who now has to take extra precautions on it.
Methicillin-resistant Staphylococcus aureus (MRSA) has rapidly become the bacteria of the decade. MRSA infections now respond only to very advanced antibiotics that were never meant to be a first-line defense. Usually, the drugs have to be delivered intravenously -- which often means spending some nights in the hospital. And it doesn't help that the state of antibiotics is falling behind. With new antibiotics being approved at slowerandslowerrates, the battle against MRSA has many doctors worrying about creating a superbug they can't kill at all. Now, new data suggest that the MRSA problem may be even worse than we thought.
MRSA is also found in a variety of common place areas including locker rooms, schools and meat/poultry plants. 25% or more of the entire meat and poultry available for consumption in the U.S. could be infected with MRSA. Needless to say, an effective combatant of this disease would be welcome in the market place, although the company might receive stiff competition from other companies who presently market, and/or develop treatments for MRSA.
The company recently announced in January a public offering of seven million shares. Often, the best time to buy a small cap biotech is right after it engages in the kind of offering Trius did. Dilution is no longer a fear factor for investors, and normally when a company shows promise, the price goes up.
Upwards Continuation pattern clearly shown with trending accumulation and RSI, to me it looks like $6 is coming very soon.
More DD to follow
Scott, what do you think about ETRM? Im am not an expert, but it seems to have potential…
I liked it before their study fail. at this time, not much going for it until company shows it can produce real results for its Maestro system, and that will be at least a year or 2 away.